A laboratory technician works at a Tsinghua University lab, which co-developed a monoclonal antibody, in Beijing on Dec 9, 2021. - AFP
BEIJING (Reuters): China's Brii Biosciences said on Sunday (Dec 12) lab studies showed that its Covid-19 antibody cocktail retained activity against the Omicron variant, although one of the antibodies showed a substantial drop in activity when tested alone.
Test details for the dual-antibody treatment, which last week became the first approved Covid-19 antibody cocktail in China, would not be available until publication in a scientific journal, but results from three independent labs showed similar pattern, Brii chief executive Hong Zhi said on Monday.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
